Anti-PD-L1 Monoclonal Antibody

Anti-PD-L1 Monoclonal Antibody


Regular price $50.00 You Pay

Supplier: GenomeMe


Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.


Clone IHC411
Source Rabbit Monoclonal
Positive Control Tonsil, Lung Adenocarcinoma
Dilution Range 1:100 - 1:200


  1. Ostrand-Rosenberg S, et al. J Immunol. 2014; 193:3835-41.

  2. Tokito T, et al. Eur J Cancer. 2016; 55:7-14.

  3. Park IH, et al. Clin Breast Cancer. 2016; 16:51-8.

  4. Kakavand H, et al. Mod Pathol. 2015; 28: 1535-44.

  5. Xia B, et al. Immunotherapy. 2016; 8:279-98.

  6. Patel SP, et al. Mol Cancer Ther. 2015; 14:847-56.

  7. Singh BP, et al. Cancers (Basel). 2016; 8.

  8. Chemnitz JM, et al. J Immunol. 2004; 173:945–54.

  9. Thompson RH, et al. Proc Natl Acad Sci USA. 2004; 101:17174–9.

  10. Hamanishi J, et al. Proc Natl Acad Sci USA. 2007; 104:3360–5.

  11. Mozaffarian N, et al. Rheumatology, 2008; 47:1335–41.